Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL Clinical Trials (2026): 1 Studies for Known or Highly Suspected Body (Excluding CNS) Lesion & Known or Highly Suspected Central Nervous System (CNS) Lesion

Where to Participate: All Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL Trial Sites in the U.S. (1 site across 1 state)

Every actively recruiting Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mLtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL clinical trials at a glance: phase × recruitment status

Recruiting Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

All Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL trials (1)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL clinical trials: frequently asked questions

How many Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL clinical trials are there?

1 Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.

Are Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL clinical trials recruiting in 2026?

Yes — 1 Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.

What conditions is Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL being studied for?

Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL is being studied for Known or Highly Suspected Body (Excluding CNS) Lesion, Known or Highly Suspected Central Nervous System (CNS) Lesion. The trials are grouped by indication on this page.

Who sponsors Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL clinical trials?

The lead sponsor across the most Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL trials is GE Healthcare. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mLas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.